Gland Pharma Limited

NSEI:GLAND Stock Report

Market Cap: ₹298.3b

Gland Pharma Valuation

Is GLAND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GLAND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GLAND (₹1810.65) is trading above our estimate of fair value (₹804.15)

Significantly Below Fair Value: GLAND is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLAND?

Key metric: As GLAND is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GLAND. This is calculated by dividing GLAND's market cap by their current earnings.
What is GLAND's PE Ratio?
PE Ratio43.1x
Earnings₹6.92b
Market Cap₹298.31b

Price to Earnings Ratio vs Peers

How does GLAND's PE Ratio compare to its peers?

The above table shows the PE ratio for GLAND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.1x
506943 J. B. Chemicals & Pharmaceuticals
46.2x19.4%₹282.5b
AJANTPHARM Ajanta Pharma
43.4x16.3%₹380.2b
IPCALAB Ipca Laboratories
62.6x30.1%₹414.2b
EMCURE Emcure Pharmaceuticals
48x25.3%₹272.4b
GLAND Gland Pharma
43.1x25.8%₹298.3b

Price-To-Earnings vs Peers: GLAND is good value based on its Price-To-Earnings Ratio (43.1x) compared to the peer average (50.1x).

Price to Earnings Ratio vs Industry

How does GLAND's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$72.12m
524652 Ind-Swift
2.8xn/aUS$18.03m
No more companies available in this PE range
GLAND 43.1xIndustry Avg. 35.3xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GLAND is expensive based on its Price-To-Earnings Ratio (43.1x) compared to the Indian Pharmaceuticals industry average (35x).

Price to Earnings Ratio vs Fair Ratio

What is GLAND's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLAND PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.1x
Fair PE Ratio46.8x

Price-To-Earnings vs Fair Ratio: GLAND is good value based on its Price-To-Earnings Ratio (43.1x) compared to the estimated Fair Price-To-Earnings Ratio (46.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GLAND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,810.65
₹1,813.25
+0.1%
26.6%₹3,120.00₹1,214.00n/a12
Dec ’25₹1,738.00
₹1,813.25
+4.3%
26.6%₹3,120.00₹1,214.00n/a12
Nov ’25₹1,646.35
₹1,920.25
+16.6%
29.0%₹3,120.00₹1,214.00n/a12
Oct ’25₹1,800.80
₹1,942.75
+7.9%
29.5%₹3,120.00₹1,214.00n/a12
Sep ’25₹1,838.55
₹1,983.58
+7.9%
28.5%₹3,120.00₹1,214.00n/a12
Aug ’25₹2,123.65
₹1,886.58
-11.2%
29.0%₹3,120.00₹1,214.00n/a12
Jul ’25₹1,818.15
₹1,827.33
+0.5%
31.2%₹3,120.00₹873.00n/a12
Jun ’25₹1,840.15
₹1,827.33
-0.7%
31.2%₹3,120.00₹873.00n/a12
May ’25₹1,711.20
₹1,845.25
+7.8%
32.5%₹3,120.00₹873.00n/a12
Apr ’25₹1,813.75
₹1,861.58
+2.6%
30.7%₹3,120.00₹1,130.00n/a12
Mar ’25₹1,787.55
₹1,876.00
+4.9%
29.4%₹3,120.00₹1,130.00n/a13
Feb ’25₹1,983.80
₹1,756.67
-11.4%
31.2%₹3,120.00₹906.00n/a15
Jan ’25₹1,906.55
₹1,669.00
-12.5%
30.3%₹3,120.00₹871.00n/a15
Dec ’24₹1,809.35
₹1,649.00
-8.9%
30.1%₹3,120.00₹871.00₹1,738.0015
Nov ’24₹1,533.95
₹1,544.33
+0.7%
34.4%₹3,120.00₹871.00₹1,646.3515
Oct ’24₹1,675.10
₹1,477.67
-11.8%
35.0%₹3,120.00₹871.00₹1,800.8015
Sep ’24₹1,768.10
₹1,477.67
-16.4%
35.0%₹3,120.00₹871.00₹1,838.5515
Aug ’24₹1,303.60
₹1,428.80
+9.6%
38.7%₹3,120.00₹925.00₹2,123.6515
Jul ’24₹1,062.50
₹1,434.80
+35.0%
38.6%₹3,120.00₹925.00₹1,818.1515
Jun ’24₹932.45
₹1,445.44
+55.0%
39.0%₹3,120.00₹925.00₹1,840.1516
May ’24₹1,358.80
₹1,734.67
+27.7%
29.7%₹3,120.00₹1,200.00₹1,711.2015
Apr ’24₹1,268.25
₹1,771.33
+39.7%
28.8%₹3,120.00₹1,200.00₹1,813.7515
Mar ’24₹1,292.75
₹1,990.63
+54.0%
45.0%₹4,930.00₹1,300.00₹1,787.5516
Feb ’24₹1,262.40
₹2,118.88
+67.8%
42.3%₹4,930.00₹1,300.00₹1,983.8017
Jan ’24₹1,576.55
₹2,547.53
+61.6%
27.8%₹4,930.00₹1,660.00₹1,906.5517
Dec ’23₹1,752.95
₹2,538.28
+44.8%
26.9%₹4,930.00₹1,800.00₹1,809.3518

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 07:34
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gland Pharma Limited is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Neha ManpuriaBofA Global Research
Vivek AgrawalCitigroup Inc